BREAST/ADJUVANT

Targeted Treatment for Advanced NSCLC. S1400F sub-study . A Phase II Study of MEDI4736 plus Tremelimumab as Therapy for Patients with Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV … ................
................